Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Tech) is a joint-stock enterprise with the combined investment of Song’an investment, Kawin Bio-Tech and Qin-Takeda, integrating R&D, manufacturing and sales of biological and chemical drugs.

Based on its advanced bio-tech platform, Kawin Tech is committed to become a professional company that provides all-round solutions in the two major fields of Hepatology and Neurology.

R&D: Led by renowned academician Dr. Hou Yunde, and through integrated innovation, Kawin Tech’s R&D team has developed a series of novel medicines with proprietary intellectual property based on national technology projects such as “11^th Five-Year Plan” and “12^th Five-Year Plan”.

Production: Kawin Tech has 7 GMP-certified production workshops for biologics and chemical drugs. Production lines include injection lines for pre-filled injection, liquid injection in vials and lyophilized powder for injection, and solid formulation lines for tablets, capsules, granules and effervescent tablets. Unmatched highest quality control systems have been established and approved by international GMP audits.

Products: Kawin Tech has market leadership position in Hepatology and Neurology, with core products such as rh Interferon Alfa-2b, Compound Glycyrrhizin and Naloxone Hydrochloride injection.

Service: With the highest product quality as core principle, Kawin Tech has set up professional market promotion teams across the country. We keep close contact with clinicians and provide them with latest medical and drug information as well as professional consultancy and academic meetings.